Pancreatic Cancer Research

ResearcherSapporo Medical UniversityActive in the last 2 years

Masafumi Imamura

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-7669-7666; OpenAlex author ID A5064506085, A5110188631. Sources: OpenAlex.

Their work

Papers
21 (first author 2, last author 1)
Trials
0
Grants
0
Labs led
0
Collaborators
109
Papers, trials and grants by year

2011: 1 paper · 2012: none · 2013: 2 papers · 2014: none · 2015: 2 papers · 2016: none · 2017: none · 2018: 1 paper · 2019: 1 paper · 2020: 2 papers · 2021: 2 papers · 2022: 1 paper · 2023: none · 2024: 1 paper · 2025: 4 papers · 2026: 4 papers

Papers 21

  1. Conversion surgery for unresectable pancreatic ductal adenocarcinoma with liver metastasis at initial diagnosis: a nationwide multicenter study. Co-author DOI 10.1007/s00535-026-02432-2↗
  2. Concordance of claudin-18.2 expression in biopsy, resection, and recurrent specimens: implications for zolbetuximab therapy in pancreatic ductal adenocarcinoma. Co-author DOI 10.1080/21688370.2025.2535047↗
  3. Clinicopathological Factors on Survival after Conversion Surgery for Unresectable Locally Advanced Pancreatic Cancer: A Nationwide Study by the Japanese Societ… Co-author DOI 10.1097/sla.0000000000007012↗
  4. Perioperative prognostic factors of early recurrence in resectable pancreatic ductal adenocarcinoma following neoadjuvant chemotherapy: A retrospective multice… Co-author DOI 10.21203/rs.3.rs-9156519/v1↗
  5. Patients With Pancreatic Cancer With Synchronous Liver Oligometastasis Show a Significant Long-Term Survival Benefit From Resection Under Specific Conditions: … Co-author DOI 10.1002/jhbp.12181↗
  6. The Role of Claudin-1 in Enhancing Pancreatic Cancer Aggressiveness and Drug Resistance via Metabolic Pathway Modulation. Co-author DOI 10.3390/cancers17091469↗
  7. Role of preoperative circulating tumor DNA in predicting occult metastases in resectable and borderline resectable pancreatic ductal adenocarcinoma. First author DOI 10.3748/wjg.v31.i32.109383↗
  8. Common Hepatic Artery Resection and Reconstruction During Pancreaticoduodenectomy Following Chemotherapy for Locally-Advanced Pancreatic Cancer: A Case Report. Last author DOI 10.7759/cureus.94956↗
  9. Predictors of occult metastases in potentially Resectable pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.sopen.2024.07.010↗
  10. HOPS-R01 phase II trial evaluating neoadjuvant S-1 therapy for resectable pancreatic adenocarcinoma. Co-author DOI 10.1038/s41598-022-14094-0↗
  11. Conversion pancreaticoduodenectomy with dual arterial reconstructions for locally advanced pancreatic cancer: Case report and literature review. First author DOI 10.1016/j.ijscr.2021.105692↗
  12. Perioperative Predictors of Early Recurrence for Resectable and Borderline-Resectable Pancreatic Cancer. Co-author DOI 10.3390/cancers13102285↗
  13. Tricellular tight junction protein LSR/angulin-1 contributes to the epithelial barrier and malignancy in human pancreatic cancer cell line. Co-author DOI 10.1007/s00418-019-01821-4↗
  14. Glucose-Dependent FOXM1 Promotes Epithelial-to-Mesenchymal Transition Via Cellular Metabolism and Targeting Snail in Human Pancreatic Cancer. Co-author DOI 10.1097/mpa.0000000000001485↗
  15. Clinical usefulness of conversion surgery for unresectable pancreatic cancer diagnosed on multidetector computed tomography imaging: Results from a multicenter… Co-author DOI 10.1002/ags3.12272↗
  16. Case report: Long-term survival of a pancreatic cancer patient immunized with an SVN-2B peptide vaccine. Co-author DOI 10.1007/s00262-018-2217-x↗
  17. Claudin-4 binder C-CPE 194 enhances effects of anticancer agents on pancreatic cancer cell lines via a MAPK pathway. Co-author DOI 10.1002/prp2.196↗
  18. Association of Fusobacterium species in pancreatic cancer tissues with molecular features and prognosis. Co-author DOI 10.18632/oncotarget.3109↗
  19. Protein kinase Cα inhibitor protects against downregulation of claudin-1 during epithelial-mesenchymal transition of pancreatic cancer. Co-author DOI 10.1093/carcin/bgt057↗
  20. Immunotherapeutic benefit of α-interferon (IFNα) in survivin2B-derived peptide vaccination for advanced pancreatic cancer patients. Co-author DOI 10.1111/cas.12046↗
  21. Transcriptional regulation of claudin-18 via specific protein kinase C signaling pathways and modification of DNA methylation in human pancreatic cancer cells. Co-author DOI 10.1002/jcb.23095↗

Closest collaborators

The 25 strongest of 109 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Yasutoshi Kimura · 15 shared papers, 2011–2025 · strength 1.55
  2. Daisuke Kyuno · 9 shared papers, 2011–2026 · strength 1.21
  3. Ichiro Takemasa · 8 shared papers, 2018–2025 · strength 1.06
  4. Makoto Yoshida · 4 shared papers, 2019–2026 · strength 0.75
  5. Satoshi Hirano · 5 shared papers, 2019–2026 · strength 0.75
  6. Sohei Satoi · 3 shared papers, 2025–2026 · strength 0.57
  7. Makoto Osanai · 2 shared papers, 2025–2026 · strength 0.56
  8. Takashi Kojima · 6 shared papers, 2011–2025 · strength 0.54
  9. Takumi Konno · 4 shared papers, 2015–2025 · strength 0.48
  10. Tatsuya Ito · 4 shared papers, 2011–2026 · strength 0.44
  11. Takeshi Murakami · 2 shared papers, 2024–2025 · strength 0.41
  12. Masayuki Sho · 2 shared papers, 2026 · strength 0.41
  13. Kenichiro Uemura · 2 shared papers, 2026 · strength 0.41
  14. Minako Nagai · 2 shared papers, 2026 · strength 0.41
  15. Michiaki Unno · 2 shared papers, 2026 · strength 0.41
  16. Masafumi Nakamura · 2 shared papers, 2025–2026 · strength 0.39
  17. Masayo Motoya · 3 shared papers, 2019–2025 · strength 0.38
  18. Shuji Suzuki · 2 shared papers, 2025–2026 · strength 0.34
  19. Masamichi Mizuma · 2 shared papers, 2025–2026 · strength 0.34
  20. Toshiya Abe · 2 shared papers, 2025–2026 · strength 0.34
  21. Tomohiro Nakajima · 1 shared paper, 2025 · strength 0.33
  22. Tõru Nakamura · 2 shared papers, 2022–2025 · strength 0.30
  23. Akira Takasawa · 3 shared papers, 2011–2025 · strength 0.28
  24. Kohichi Takada · 1 shared paper, 2026 · strength 0.26
  25. Joji Muramatsu · 1 shared paper, 2026 · strength 0.26

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.